

BIBLIOGRAPHY for “Irofulven – Halloween Trick or a Beacon of Light”

Amato RJ, Perez C, Pagliaro L. **2002**. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer. *Invest. New. Drugs* 20(4): 413-417.

Anchel M, Hervey A, Robins W. **1950**. Antibiotic substances from basidiomycetes *Clitocybe illudens*. *Proc. Nat. Acad. Sciences USA*. 36(5): 300-305.

Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. **2000**. Phase I and pharmacokinetic study of Irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. *J. Clin. Oncology* 18(24): 4086-4097.

Kelner MJ, McMorris TC, Estes LA, Starr RJ, Rutherford M, Montoya M, Samson K and Taetle R. **1995**. Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various MDR phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. *Cancer Res.* 55: 4936-4940AA.

Kelner MJ, McMorris TC, Estes L, Samaon KM, Trani NA, MacDonald RJ. **2000**. Anti-leukemic action of the novel agent MGI-114 (HMAF) and synergistic action with topotecan. *Leukemia* 14(1): 136-141.

Kelner MJ, McMorris TC, Montoya MA, Estes L, Rutherford M, Samson KM, Taetle R. **1997**. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. *Cancer Chemother Pharmacol.* 40(1): 65-71.

Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. **2008** Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with alteramine, alkylating, and platinum-derived agents in the MV522 lung tumor model. *Cancer Chemo. Pharmacol.* [original article DOI! 10/1007/s00280-008-0703-0, Feb 6, 2008]

Kelner MJ, McMorris TC, Taetle R. **1990**. Prclinical evaluation of illudins as anticancer agents: Basis for selective cytotoxicity. *J. Natl. Cancer Inst.* 82(19): 1562-1565.

Kirchmair M, Morandell S, Stolz D, Poder R, Sturmbauer C. **2004**. Phylogeny of the genus *Omphalotus* based on nuclear ribosomal DNA-sequences. *Mycologia* 96(6): 1253-1260.

Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH. **2005**. Cone damage in patients receiving high-dose irofulven treatment. *Arch. of Ophthal.* 123(1): 29-34.

Lehmann VKB, Huang A, Ibanez-Calero S, Wilson GR, Rinehart K. **2003**. Illudin S, the sole antiviral compound in mature fruiting bodies of *Omphalotus illudens*. J. Nat. Prod. 66(9): 1257-1258.

Liang H, Salinas RA, Leal BZ, Kosakowska-Cholody T, Michejda CJ, Waters SJ, Herman TS, Woynarowski JM, Woynarowska BA. **2004**. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. Mol. Cancer Ther. 3(11): 1385-96.

McMorris TC. **1999**. Total synthesis of antitumor acylfulvenes. USP 5856580.

McMorris TC, Anchel M. **1963**. The structures of the basidiomycete metabolites illudin S and illudin M. J. Amer. Chem. Soc. 85:831.

McMorris TC, Anchel M. **1965**. Fungal metabolites. The structures of the novel sesquiterpenoids illudin S and M. J. Amer. Chem. Soc. 87: 1594-1600.

McMorris TC, Elayadi AN, Yu J, Hu Y, Kelner MJ. **1999**. Metabolism of antitumor Hydroxymethylacylfulvene by rat liver cytosol. Drug Metab. Disposition 27(9): 983-985.

McMorris TC, Kelner MJ, Wang W, Moon S and Taetle R. **1990**. On the mechanism of toxicity of illudins: The role of glutathione. Chem. Res. Toxicol 3: 574-579.

McMorris TC, Kelner MJ, Wang W, Diaz MA, Estes LA and Taetle R. **1996a**. Acylfulvenes, a new class of potent antitumor agents. Experientia 52: 75-80.

McMorris TC, Kelner MJ, Wang W, Yu J, Estes LA and Taetle R. **1996b**. (Hydroxymethyl)acylfulvene: An illudin derivative with superior antitumor properties. J. Nat. Prod. 59: 896-899.

MGI Pharma – http://www.mgipharma.com/wt/page/history_1993.

Murgo A, Cannon DJ, Blatner G and Cheson BD. **1999**. Clinical trials of MGI 114. Oncology 13: 233-238.

Nair MSR, Carey ST, Rogerson CT. **1983**. Illudoids from *Omphalotus olivaescens* and *Clitocybe subilludens*. Mycologia 75(5): 920-922.

Poindessous V, Koepfel F, Raymond E, Comisso M, Watters SJ, Larsen AK. **2003**. Marked activity of irofulven toward human Carcinoma cells. Clin. Cancer Res. (9): 2817-2825.

Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandere J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E. **2004**. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent Phase I and II trials. Clinical Cancer Research 19: 7555-7574.

Samuels GJ, Fogel R. **2003**. Clark Thomas Rogerson, 1918-2001. *Mycologia* 95(4): 773-779.

Sato Y, Kashimoto S, MacDonald JR, Nakano K. **2001**. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumor xenograft models including several lung and gastric tumors. *Europ. J. of Cancer*. 37(11): 1419-28.

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire P III. **2005**. A Phase II study of irifulven in women with recurrent and heavily pretreated ovarian cancer. *Gyn. Oncol.* 101(1): 55-61.

Sezner N, Arsenau J, Richard D, Berman B, MacDonald JR, Smith S. **2005**. Irifulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a Phase 2 single-agent trial. *Am. J. of Clin. Oncol.* 28(1): 36-42.

Wojnarowska BA, Wojnarowski JM. **2002**. Preferential targeting of apoptosis in tumor versus normal cells. *Biochem. Biophys. Acta (BBA) – Molecular Basis of Disease*, vol. 1587 (2-3): 309-317.